ImpediMed Limited (IPD) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the Impedimed Investor Call Q4 FY25 results call. All participants are in a listen-only mode. There will be a presentation followed by a question and answer session. If you wish to ask a question, you'll need to press the star key followed by the number one on your telephone keypad. I would now like to hand the conference over to Ms. Palmjot Baines, CEO and MD. Please go ahead. Thank you. Good morning and thank you for joining us to discuss the quarter four FY25 results. I'm pleased to be here with McGregor Grant, our CSO. We will be referencing the 4C quarterly activity report and presentation that we lodged this morning with the ASX. The presentation is a summary of the more detailed 4C. After our remarks, we'll be taking questions. It's been another busy and encouraging quarter. clear signs that the strategy we've been working hard on is starting to pay off. We recorded our highest ever total contract value this quarter, which is a fantastic achievement. On top of that, a major commercial pay began coverage, something we believe will have a significant impact going forward. We also achieved the key goals that we set for ourselves, including exceeding our sales target to trigger access to the next tranche of our debt facility and exceeding the cost reduction targets we put in place. The American Society of Breast Surgeons Conference was another highlight last quarter. It was led by our new VP of Sales, Scott Long, and gave us a great opportunity to connect with both current and potential customers. What really stood out was the importance of survivorship in cancer care, and more and more clinicians turning to SOZO to lower the lymphedema risk for their patients. This quarter, we also initiated a measured expansion into two n...